CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Recruiting now · Phase 3
Conditions studied: Acute Myeloid Leukemia in Children
In brief
The CHIP-AML22 Master protocol has the overall aim of increasing the cure rate in newly diagnosed pediatric de novo AML patients, while avoiding unnecessary toxicity.
Key facts
- Study ID
- NCT05994690
- Run by
- Princess Maxima Center for Pediatric Oncology
- People needed
- 905
- Starts
- 2023-07-14
- Expected to finish
- 2035-12-01
- Last updated by the study team
- 2025-08-05
Who can join
Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Princess Máxima Center for pediatric oncology — Utrecht, Utrecht, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.